AOI Nagpur Celebrates Success With Consecutive Bloodless Bone Marrow Transplants

American Oncology Institute (AOI) at Nangia Specialty Hospital in Nagpur has reached a significant milestone in cancer care by successfully performing two consecutive bloodless autologous bone marrow transplants for Multiple Myeloma (MM) patients. 

The oncology institute in a press statement on Tuesday said that the procedures, conducted on a 58-year-old male from Amravati and a 57-year-old male from Madhya Pradesh, were led by Dr. Shailesh Bamborde, a BMT Specialist, and his dedicated team. These transplants utilised the patient’s own cells, thereby minimising the risk of infection and rejection.

Harish Trivedi, CEO of CTSI - South Asia, commented on the broader impact of AOI Nagpur’s advancements: "AOI Nagpur's achievement in bloodless bone marrow transplants marks a significant milestone in advancing healthcare accessibility in Central India. This innovation underscores their commitment to delivering high-quality care and reducing healthcare disparities in the region."

Multiple Myeloma is a prevalent type of blood cancer that arises from plasma cells in the bone marrow, accounting for about 10-15% of blood cancers. It presents symptoms such as renal failure, anaemia, bone pain, infections, and fatigue. The bloodless transplant technique employed by AOI Nagpur offers new hope for effective treatment and improved quality of life for patients battling this complex disease.

Dr. Amit Dhawan, Regional Chief Operating Officer of AOI Nagpur, emphasised the institution’s dedication to excellence in cancer care: "AOI Nagpur is dedicated to offering world-class medical care with compassion and affordability. Our recent success in bloodless bone marrow transplants signifies our capability to provide cutting-edge treatments locally, reducing the burden on patients and their families."

Dr. Shailesh Bamborde, BMT Specialist at AOI Nagpur, highlighted the significance of the procedure: “Treatment of Multiple Myeloma has evolved remarkably in the last few decades. Improved understanding of myeloma biology has led to advances in diagnosis, prognosis, and response assessment, resulting in impressive improvements in patient survival rates. With our bloodless autologous transplant approach, we use the patient's own stem cells to rejuvenate their marrow, minimizing risks and optimizing recovery. This method not only ensures safety but also improves long-term outcomes for our patients.”